Contraindications to the use of drugs: AV-block II and III. without pacemaker; blockade legs right bundle Hissa simultaneously with the blockade Quart one of the branches of the left legs beam Hissa (bifastsykulyarna block) without pacemaker; congestive heart failure, cardiogenic shock (except arytmohennoho) severe symptomatic bradycardia (heart rate <50 beats / min); SSSV; arterial hypotension (systolic blood parameters of AT <90 mm Hg), hypokalemia, hyperkalemia (no circuit correction potassium exchange violations prior to treatment), severe hr. obstructive lung disease, myasthenia gravis, hypersensitivity to medication, severe hepatic failure. Method of additive operator of drugs: Table., Coated tablets, 150 mg, 300 mg. states. The main effect of pharmaco-therapeutic effects of drugs: antianginal, antihypertensive, antiarrhythmic action; cardioselective ?1-adrenoceptor blocker with rapid onset and a very small duration, in therapeutic doses has no sympatomimetychnoyi and membranstabilizuyuchoyi activity, reduces catecholamines stimulated cAMP formation from ATP, reduces intracellular Ca2 + flow, reduces heart rate, slows conduction, reduces skorotnist infarction effect of the drug starts with Since the introduction, the Iron therapeutic effect develops in 2 minutes after administration and ending 10-20 min after cessation of infusion, has enzymatic labile essential link. Indications for use drugs: treatment SUPRAVENTRICULAR tachycardias such as AV-nodal tachycardia, supraventykulyarna tachycardia in patients with WPW c-IOM and paroxysmal form of atrial fibrillation, ventricular tahiarytimiyi Nuclear Medicine Dosing and Administration of drugs: the additive operator dose for adults - the therapeutic dose for patients weighing 70 kg, as typically here 450 - 600 mg / day (150 mg 3 g / day or 300 mg, 2 g / day) in some Platelets may require increase daily dose additive operator 900 mg (300 mg 3 g / day) - MDD, patients with lower body weight to reduce the dose; increase the recommended dose gradually, at intervals of 3-4 days, the duration of treatment is determined by the clinical condition of the patient. Pharmacotherapeutic group: S07AV09 - selective antagonists of ?-blockers. Pharmacotherapeutic group: S01VS03 - antiarrhythmic and class. Method of production of drugs: Mr injection, 10 mg / ml to 10 ml vial. Pharmacotherapeutic group: S01BD01 - Class III antiarrhythmic drugs. The main pharmaco-therapeutic action: the antiarrhythmic action and has a moderate blocking effect on ?-adrenoreceptors, decreases the maximum rate of depolarization and action potential amplitude in purkinje fibers do not affect the resting potential, the most pronounced effect is registered in the system Hissa-purkinje; demonstrate the efficiency of organic heart lesions, including patients who have suffered MI.
Nenhum comentário:
Postar um comentário